Popular on TelAve
- L2 Aviation Announces Strategic Growth Investment from Argentum - 107
- Desert Water SL and Planet Alpha Corp. map carbon for the country of Sierra Leone using satellite data for conservation and the creation of carbon
- Sycamore Hills Dentistry Welcomes the Yomi Robot: The Future of Dental Implant Surgery
- Hoffman Homes Unveils New Brand
- Zoiko Telecom joins BT Wholesale's Partner Plus to bring enhanced connectivity to UK customers
- GitKraken Launches DevEx Advance Partner Program to Help Atlassian Solution Partners Elevate Their Clients' Developer & DevOps Team Productivity
- Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression NRx Pharmaceuticals: NRXP
- Energies Media: Unifying Insights Across the Energy Spectrum
- Tobu Railway Group's Tobu Kogyo Division Has Renovated the Kotoku Cattle Farm in Nikko National Park and Reopened it as of July 1, 2024
- CCHR Seeks Redress for Those Forcibly Held and Harmed in Behavioral Facilities
Similar on TelAve
- Evergreen Property Partners Announces DJ Van Keuren's Recognition as One of the World's Top 50 Family Capital Advisors
- ALLTRA SmartChain (OZZ METALS LTD) Secures Full Funding
- Bent Danholm's Innovative Targeted Marketing Approach Sells Homes Faster and More Profitable
- VerifyNow Launches Groundbreaking FICA Compliance Platform for South African Businesses
- Webinar Announcement: Creative Methods for Tracing Assets
- Diversified Industrial Acquisition Agreement, Plus Major Contract Award for Large Fleet Trucking Provider: MingZhu Logistics: Stock Symbol: YGMZ
- L2 Aviation Announces Strategic Growth Investment from Argentum
- AdvisorVault's 17a-4 Managed 365 Service: Finally, Guaranteed FINRA Compliance On The Microsoft Cloud
- CCHR Seeks Redress for Those Forcibly Held and Harmed in Behavioral Facilities
NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
TelAve News/10840215
Substantial Funding Agreements, Debt Resolution and Successful Clinical Trial Progress Towards Accelerated Drug Approval
RADNOR, Pa. - TelAve -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"
In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.
More on TelAve News
The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.
NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.
NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.
The potential of these two NRXP therapies is monumental. Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes. Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.
The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.
It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.
More on TelAve News
Participation at New York Global Investment Conference
NRXP has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.
Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
NRXP has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.
To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"
In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.
More on TelAve News
- NBA Champion Derek Anderson and Jamie Anderson Celebrate Anniversary and Community Impact
- Dallas Cowboys Sign the State of Nayarit as their Official Mexican Tourism Destination
- Emory Healthcare Systemwide Allied Health Hiring Event at the High Museum of Art
- TurnMississippiBlue.org Pledges A New Way Forward
- HandicapMD Expands Leading Telemedicine Services for Disabled Parking Permits in Florida
The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.
NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.
NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.
The potential of these two NRXP therapies is monumental. Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes. Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.
The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.
It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.
More on TelAve News
- Democracy at Work & The Left Forum Presents Seminar with Professor Richard D. Wolff based on "Understanding Capitalism"
- Decorate for Fall with Braided Rugs
- HandicapMD.com Expands Its Leading Telemedicine Service for Disabled Parking Placards in California
- ALLTRA SmartChain (OZZ METALS LTD) Secures Full Funding
- Boston Industrial Solutions, Inc. Glass Primer delivers unmatched UV ink durability for glass, tiles, and ceramics
Participation at New York Global Investment Conference
NRXP has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.
Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
NRXP has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.
To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on TelAve News
- Webinar Announcement: Creative Methods for Tracing Assets
- NEMTAC Announces New Board of Directors Officers for 2024-2025
- Dehy Mills Welcomes Two New Board Members to Support Future Growth
- Stars of Netflix's 'Skywalkers:A Love Story' Scale World's Tallest Bridge Inspired by $DOGS Community
- CCHR: "Family Estrangement" Used to Detain and Abuse Children in Psych Hospitals
- GoGo Roofing Introduces Expanded Services: Now Offering Roofing Solutions in New Georgia Communities
- Atlas Elite Entertainment Releases New Single "Forever"
- "Monotheism and Devils" is the theologically dedicated sequel of "Prince of Eurasia" of the Islamic cleric and executive producer Prince Oak Oakleyski
- Vantiva Wins CSI Award for "Best Sustainability Project or Initiative" for Eco-Friendly V7c Android TV Set Top Box
- Inframark Announces New Chief Financial Officer
- Cellhire Wins Connectivity Gold at the Paris 2024 Games
- VVC Ready for Deployment: An Exclusive Conversation with Lukasz Litwic at IBC 2024
- Hayloft Big Creek Now Pre-Leasing
- Green Office Partner Ranked #1 on Crain's 2024 List of Best Places to Work in Chicago
- Diversified Industrial Acquisition Agreement, Plus Major Contract Award for Large Fleet Trucking Provider: MingZhu Logistics: Stock Symbol: YGMZ
- Messageware Z-Day Guard v1.5 Expands MDR Security to Azure, Exchange, and Windows Servers
- The Ripple Effect Arts, has launched its latest product, Organic Wild Yam Cream, capitalizing on the company's recent viral success on TikTok
- Prince of Eurasia: Monotheism and Devils — the ultrarare Eurasian theological documentary of executive producer Prince Oak Oakleyski
- Vimaan Named in the Gartner® Hype Cycle™ Reports, 2024 for Autonomous Data Collection and Inspection
- Vantiva Unveils ONYX, its latest Smart Media Device with Advanced AI Capabilities at IBC 2024